Last10K.com

Mymd Pharmaceuticals, Inc. (MYMD) SEC Filing 10-Q Quarterly Report for the period ending Thursday, June 30, 2022

Mymd Pharmaceuticals, Inc.

CIK: 1321834 Ticker: MYMD
Cover - shares
6 Months Ended
Jun. 30, 2022
Aug. 12, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateJun. 30, 2022 
Document Fiscal Period FocusQ2 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--12-31 
Entity File Number001-36268 
Entity Registrant NameMyMDPharmaceuticals, Inc. 
Entity Central Index Key0001321834 
Entity Tax Identification Number22-2983783 
Entity Incorporation, State or Country CodeNJ 
Entity Address, Address Line One855N. Wolfe Street 
Entity Address, Address Line TwoSuite 601 
Entity Address, City or TownBaltimore 
Entity Address, State or ProvinceMD 
Entity Address, Postal Zip Code21205 
City Area Code(856) 
Local Phone Number848-8698 
Title of 12(b) SecurityCommon Stock, no par value per share 
Trading SymbolMYMD 
Security Exchange NameNASDAQ 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 38,058,245

View differences made from one quarter to another to evaluate Mymd Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Mymd Pharmaceuticals, Inc..

Continue

Assess how Mymd Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Mymd Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
M & A
Revenue
Legal
Other
Filter Subcategory:
All
Shares
Expense
Debt
Product
Dividend
Other
Inside Mymd Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statement Of Changes In Shareholders' Equity (Unaudited)
Condensed Consolidated Statement Of Changes In Shareholders' Equity (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Comprehensive Loss (Unaudited)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Employee Benefit Plan
Employee Benefit Plan (Details Narrative)
Equity
Equity (Details Narrative)
Equity (Tables)
Notes Payable
Notes Payable (Details Narrative)
Organization And Description Of Business
Organization And Description Of Business (Details Narrative)
Patent Assignment And Royalty Agreement
Paycheck Protection Program Loan
Paycheck Protection Program Loan (Details Narrative)
Recent Developments, Liquidity And Management???S Plans
Recent Developments, Liquidity And Management???S Plans (Details Narrative)
Recent Developments, Liquidity And Management???S Plans (Tables)
Related Parties
Related Parties (Details Narrative)
Schedule Of Anti-Dilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Condensed Consolidated Balance Sheet Information Related To Operating Lease (Details)
Schedule Of Estimated Useful Lives Of Property Plant And Equipment (Details)
Schedule Of Lease Cost (Details)
Schedule Of Marketable Securities (Details)
Schedule Of Net Assets Acquired To Be Allocated To Goodwill (Details)
Schedule Of Operating Lease Minimum Lease Payments (Details)
Schedule Of Other Information Related To Leases (Details)
Schedule Of Trade And Other Payables (Details)
Significant Accounting Policies
Significant Accounting Policies (Details Narrative)
Significant Accounting Policies (Policies)
Significant Accounting Policies (Tables)
Stock-Based Payments
Stock-Based Payments (Details Narrative)
Stock-Based Payments (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Milestone Events Payment (Details)
Summary Of Restricted Stock Units Activity (Details)
Summary Of Stock Options Activity (Details)
Summary Of Warrant Activity (Details)
Trade And Other Payables
Trade And Other Payables (Tables)
Ticker: MYMD
CIK: 1321834
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-022611
Submitted to the SEC: Mon Aug 15 2022 8:31:19 AM EST
Accepted by the SEC: Mon Aug 15 2022
Period: Thursday, June 30, 2022
Industry: In Vitro And In Vivo Diagnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/mymd/0001493152-22-022611.htm